Marshall Fordyce, PRESIDENT AND CEO at Vera Therapeutics, Inc. (VERA), sold 35,000 shares at $43.52 ($1.5M) on 2024-12-18, disclosed to the SEC on 2024-12-20.
Scheduled sale ($1.5M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $41.33 | 3,772 | $156K | 10.3% |
| 2 | $41.33 | 3,772 | $156K | 10.3% |
| 3 | $42.35 | 2,195 | $93K | 6.2% |
| 4 | $42.35 | 2,195 | $93K | 6.2% |
| 5 | $43.52 | 5,023 | $219K | 14.5% |
| 6 | $43.52 | 5,023 |
| $219K |
| 14.5% |
| 7 | $43.81 | 1,875 | $82K | 5.4% |
| 8 | $43.81 | 1,875 | $82K | 5.4% |
| 9 | $44.03 | 4,635 | $204K | 13.5% |
| 10 | $44.03 | 4,635 | $204K | 13.5% |
| Total | $43.07 avg | 35,000 | $1.5M | 100% |
| Filing → |
| VERA | SELL | 2026-07-09 | $2.0M | — | Filing → |
| VERA | SELL | 2026-06-24 | $702K | — | Filing → |
| VERA | SELL | 2026-05-13 | $680K | — | Filing → |